

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



China Wah Yan Healthcare Limited

中國華仁醫療有限公司

(Incorporated in the Hong Kong with limited liability)

(Stock Code: 648)

POLL RESULTS OF EXTRAORDINARY GENERAL MEETING AND COMPLETION OF THE SALE AND PURCHASE AGREEMENT

POLL RESULTS OF THE EGM

The Company is pleased to announce that the Resolution was duly passed by the Shareholders by way of poll at the EGM held on Monday, 31 July 2017.

COMPLETION OF THE SALE AND PURCHASE AGREEMENT

Following the passing of the Resolution, all conditions to the Sale and Purchase Agreement have been fulfilled and Completion took place on 31 July 2017 in accordance with the terms of the Sale and Purchase Agreement. Upon Completion, the Company has ceased to hold any shares in Rui Kang Pharmaceutical and Rui Kang Pharmaceutical has ceased to be a subsidiary of the Company.

Reference is made to the circular (the “Circular”) and the notice of the EGM (the “Notice”) of China Wah Yan Healthcare Limited (the “Company”) dated 14 July 2017 relating to the Disposal. Unless otherwise stated herein, capitalised terms used in this announcement shall have the same meaning as those defined in the Circular.

POLL RESULTS OF THE EGM

The Company is pleased to announce that, the ordinary resolution (the “**Resolution**”) as set out in the Notice was duly passed by the Shareholders by way of poll at the EGM held on Monday, 31 July 2017.

The poll results in respect of the Resolution are as follows:

Ordinary Resolution	Number of Shares represented by votes cast (% to the number of Shares voted at the EGM)	
	For	Against
To (i) approve the Sale and Purchase Agreement and the transactions contemplated thereby; and (ii) authorise the Directors, for and on behalf of the Company, to do all such acts and things and to sign, execute, seal (where required) and deliver all such documents and to take all such steps as the Directors in their discretion may consider necessary, appropriate, desirable or expedient to give effect to or implement or in connection with or incidental to the Sale and Purchase Agreement and/or any and all of the transactions contemplated thereunder.	1,421,370,294 (99.864%)	1,930,600 (0.136%)

* *The full text of the Resolution is set out in the Notice.*

As more than 50% of the votes were cast in favour of the Resolution, the Resolution was duly passed as an ordinary resolution of the Company.

As at the date of the EGM, there are 6,520,736,569 Shares in issue, which represent the total number of Shares entitling the Shareholders to attend and vote for or against the Resolution proposed at the EGM. As stated in the Circular, no Shareholders were required under the Listing Rules to abstain from voting on the Resolution at the EGM. There were no Shares entitling the Shareholders to attend and abstain from voting in favour of the Resolution at the EGM as set out in Rule 13.40 of the Listing Rules. In addition, no parties have stated their intention in the Circular to vote against the Resolution or to abstain from voting on the Resolution at the EGM. The Company’s share registrar in Hong Kong, Tricor Tengis Limited, was appointed as the scrutineer for the purpose of vote-taking at the EGM.

COMPLETION OF THE SALE AND PURCHASE AGREEMENT

Following the passing of the Resolution, all conditions to the Sale and Purchase Agreement have been fulfilled and Completion took place on 31 July 2017 in accordance with the terms of the Sale and Purchase Agreement.

Upon Completion, the Company has ceased to hold any shares in Rui Kang Pharmaceutical and Rui Kang Pharmaceutical has ceased to be a subsidiary of the Company.

By Order of the Board of
China Wah Yan Healthcare Limited
Lam Sung Him Gaston
Company Secretary

Hong Kong, 31 July 2017

As at the date of this announcement, the Board comprises three executive Directors, namely Mr. Chan Ka Chung, Mr. Cheung Wai Kwan and Mr. Wang Jianguo; and three independent non-executive Directors, namely, Mr. Chan Yee Ping, Michael, Ms. Hu Xuezhen and Mr. Lam Chun Ho.